Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice

Table 1 TH1 polarization assay with an IFN-γ ELISPOT method. (mean ± SD, n = 18)

	Peptide1	Peptide2	Peptide3	MART-127-35	Negative controls
ISC/106 lymphocytes	1 150 ± 236.7d	1 367 ± 231d	8 050 ± 1 233.8db	1 135 ± 312	250 ± 138

^dP < 0.01 vs negative control;

^bP < 0.01 vs peptide1 and 2 groups.

Table 2 Percentages of specific targets lysis by effector CTLs induced with different peptide antigens (mean ± SD, n = 18)

E/T ratios	Percentage of specific cell lysis (%)
	Peptide1d	Peptide2	Peptide3	MART-127-35	Negative controls
12.5	18.5 ± 4.3d	21.1 ± 6.3d	33.7 ± 7.2db	3.7 ± 0.7	5.5 ± 0.9
2 5	22.9 ± 5.7d	28.5 ± 6.6d	40.5 ± 8.9db	6.3 ± 0.9	4.4 ± 0.9
5 0	29.3 ± 7.0d	30.5 ± 8.8d	50.3 ± 11.3db	7.1 ± 1.1	7.7 ± 1.2
100	32.6 ± 10.1d	33.1 ± 8.2d	55.3 ± 10.1db	8.4 ± 1.3	9.2 ± 1.3

^dP < 0.01 vs negative control;

^bP < 0.01 vs peptide1 and 2 groups.